

CONTENTS

1. INTRODUCTION	1
1.1 Haemostasis and Thrombosis	1
1.1.1 Haemostasis	1
1.1.2 Thrombosis	2
1.2 Coagulation cascade	3
1.3 Antithrombotic drug therapy	7
1.3.1 Antiplatelet agents	7
1.3.2 Anticoagulants	10
1.3.2.1 Vitamin K-antagonists	11
1.3.2.2 Heparin and derivatives	12
1.3.2.3 Factor Xa inhibitors	13
1.3.2.4 Thrombin Inhibitors	21
1.3.3 Fibrinolytic or thrombolytic agents	27
1.4 Advantages and drawbacks of current antithrombotic drug therapy	28
1.5 Future Scope and Perspectives	29
1.6 References	33
2. LITERATURE REVIEW	41
2.1 Factor Xa inhibitors	41
2.1.1 Piperazinyll amides	41
2.1.2 Anthranilamides	42
2.1.3 Oxazolidinone analogs	52
2.1.4 Pyrimidinone analogs	53
2.2 Thrombin inhibitors	53
2.2.1 Pyrazinone derivatives	53
2.2.2 Dabigatran mimics	56
2.2.3 Allosteric thrombin inhibitors	66
2.3 References	68
3 AIM AND OBJECTIVES	75

4	RESULT AND DISCUSSION	79
4.1	Anthranilamide-based Factor Xa inhibitors	79
4.1.1	Synthesis of piperazinyl anthranilamide derivatives	79
4.1.1.1	Synthesis of substituted 2-(hydroxyimino)-<i>N</i>-phenylacetamide derivatives (159-161)	81
4.1.1.2	Synthesis of substituted indoline-2,3-diones (162-164)	81
4.1.1.3	Synthesis of substituted 2-aminobenzoic acids (165-167)	82
4.1.1.4	Synthesis of substituted benz[<i>d</i>][1,3]oxazin-4-one derivatives (168-175)	83
4.1.1.5	Synthesis of substituted anthranilamides (177-235)	86
4.1.2	Biological evaluation	115
4.1.2.1	<i>In vitro</i> FXa enzyme inhibition study	115
4.1.2.2	<i>Ex vivo</i> prothrombin time (PT) and activated partial thromboplastin time (aPTT) prolongation in rats	117
4.1.2.3	<i>In vivo</i> bleeding time in rats	118
4.1.3	Molecular docking and simulation studies	120
4.1.4	Prediction of physicochemical and pharmacokinetics properties	126
4.2	Furanopyrimidinone-based Thrombin inhibitors	127
4.2.1	Synthesis of Furanopyrimidinone-amide derivatives	127
4.2.1.1	Synthesis of diethyl 2-amino-5-methylfuran-3,4-dicarboxylate (238)	129
4.2.1.2	Synthesis of ethyl 2-(chloromethyl)-3,4-dihydro-6-methyl-4-oxofuro[2,3-<i>d</i>]pyrimidine-5-carboxylate (239)	129
4.2.1.3	Synthesis of ethyl 2-chloromethyl-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3-<i>d</i>]pyrimidine-5-carboxylate (240)	130
4.2.1.4	Synthesis of ethyl 2-((arylamino/oxy)methyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3-<i>d</i>]pyrimidine-5-carboxylate derivatives (242-251)	131
4.2.1.5	Synthesis of 2-((arylamino)methyl)-3,4-dihydro-3,6-dimethyl-4-oxo-<i>N</i>-phenethylfuro[2,3-<i>d</i>]pyrimidine-5-carboxamide derivatives (253-282).	136
4.2.2	Biological evaluation	152
4.2.2.1	<i>In vitro</i> FIIa (thrombin) enzyme inhibition study	152
4.2.2.2	<i>Ex-vivo</i> prothrombin time (PT) and activated partial	155

	thromboplastin time (aPTT) prolongation and bleeding time in rats	
4.2.3	Molecular docking studies	157
4.2.4	Prediction of physicochemical and pharmacokinetic properties	159
4.3	References	160
5	EXPERIMENTAL	162
5.1	Chemical work	162
5.1.1	2-(Hydroxyimino)- <i>N</i> -(4-methoxyphenyl)acetamide (159)	162
5.1.2	2-(Hydroxyimino)- <i>N</i> -(3,4-dimethoxyphenyl)acetamide (160)	163
5.1.3	2-(Hydroxyimino)- <i>N</i> -(4-chlorophenyl)acetamide (161)	163
5.1.4	5-Methoxyindoline-2,3-dione (162)	163
5.1.5	5,6-Dimethoxyindoline-2,3-dione (163)	164
5.1.6	5-Chloroindoline-2,3-dione (164)	164
5.1.7	2-Amino-5-methoxybenzoic acid (165)	164
5.1.8	2-Amino-4,5-dimethoxybenzoic acid (166)	165
5.1.9	2-Amino-5-chlorobenzoic acid (167)	165
5.1.10	2-(4-Chlorophenyl)-6-methoxy-4 <i>H</i> -benz[<i>d</i>][1,3] oxazin-4-one (168)	165
5.1.11	2-(4-Chlorophenyl)-6,7-dimethoxy-4 <i>H</i> -benz[<i>d</i>][1,3] oxazin-4-one (169)	166
5.1.12	6-Chloro-2-(4-chlorophenyl)-4 <i>H</i> -benz[<i>d</i>][1,3] oxazin-4-one (170)	166
5.1.13	2-(5-Chlorothiophen-2-yl)-6-methoxy-4 <i>H</i> -benz[<i>d</i>][1,3] oxazin-4-one (171)	166
5.1.14	2-(5-Chlorothiophen-2-yl)-6,7-dimethoxy-4 <i>H</i> -benz[<i>d</i>][1,3] oxazin-4-one (172)	167
5.1.15	6-Chloro-2-(5-chlorothiophen-2-yl)-4 <i>H</i> -benz[<i>d</i>][1,3] oxazin-4-one (173)	167
5.1.16	2-(6-Chloropyridin-3-yl)-6,7-dimethoxy-4 <i>H</i> -benz[<i>d</i>][1,3] oxazin-4-one (174)	167
5.1.17	6-Chloro-2-(6-chloropyridin-3-yl)-4 <i>H</i> -benzo[<i>d</i>][1,3] oxazin-4-one (175)	168
5.1.18	4-Chloro- <i>N</i> -(2-(4-(2-chlorophenyl)-1-piperazinylcarbonyl)- 4-methoxyphenyl)- benzamide (177)	168

5.1.19	4-Chloro- <i>N</i> -(2-(4-(2-fluorophenyl)-1-piperazinylcarbonyl)-4-methoxyphenyl)-benzamide (178)	169
5.1.20	4-Chloro- <i>N</i> -(2-(4-(4-fluorophenyl)-1-piperazinylcarbonyl)-4-methoxyphenyl)-benzamide (179)	169
5.1.21	4-Chloro- <i>N</i> -(2-(4-(4-methoxyphenyl)-1-piperazinylcarbonyl)-4-methoxyphenyl)-benzamide (180)	170
5.1.22	4-Chloro- <i>N</i> -(2-(4-(4-cyanophenyl)-1-piperazinylcarbonyl)-4-methoxyphenyl)-benzamide (181)	170
5.1.23	4-Chloro- <i>N</i> -(2-(4-(4-methylphenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl) benzamide (182)	171
5.1.24	4-Chloro- <i>N</i> -(2-(4-(2-methylphenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl) benzamide (183)	171
5.1.25	4-Chloro- <i>N</i> -(2-(4-(2-methoxyphenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-benzamide (184)	172
5.1.26	4-Chloro- <i>N</i> -(2-(4-(4-methoxyphenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-benzamide (185)	173
5.1.27	4-Chloro- <i>N</i> -(2-(4-(4-chlorophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)- benzamide (186)	173
5.1.28	4-Chloro- <i>N</i> -(2-(4-(4-fluorophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-benzamide (187)	174
5.1.29	4-Chloro- <i>N</i> -(2-(4-(2-fluorophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-benzamide (188)	175
5.1.30	4-Chloro- <i>N</i> -(2-(4-(2-cyanophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-benzamide (189)	175
5.1.31	4-Chloro- <i>N</i> -(2-(4-(4-cyanophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-benzamide (190)	176
5.1.32	4-Chloro- <i>N</i> -(2-(4-(4-nitrophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-benzamide (191)	176
5.1.33	4-Chloro- <i>N</i> -(2-(4-(4-aminophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-benzamide (192)	177
5.1.34	4-Chloro- <i>N</i> -(4-chloro-2-(4-(2-methylphenyl)-1-piperazinyl carbonyl)-phenyl)-benzamide (193)	177
5.1.35	4-Chloro- <i>N</i> -(4-chloro-2-(4-(2-methoxyphenyl)-1-piperazinyl carbonyl)-phenyl)-benzamide (194)	178

5.1.36	4-Chloro- <i>N</i> -(4-chloro-2-(4-(4-methoxyphenyl)-1-piperazinyl carbonyl)-phenyl)-benzamide (195)	179
5.1.37	4-Chloro- <i>N</i> -(4-chloro-2-(4-(4-fluorophenyl)-1-piperazinyl carbonyl)-phenyl)-benzamide (196)	179
5.1.38	4-Chloro- <i>N</i> -(4-chloro-2-(4-(4-cyanophenyl)-1-piperazinyl carbonyl)-phenyl)-benzamide (197)	180
5.1.39	5-Chloro- <i>N</i> -(2-(4-(2-methylphenyl)-1-piperazinyl carbonyl)-4-methoxyphenyl)-thiophene-2-carboxamide (198)	180
5.1.40	5-Chloro- <i>N</i> -(2-(4-(4-methoxyphenyl)-1-piperazinyl carbonyl)-4-methoxyphenyl)-thiophene-2-carboxamide (199)	181
5.1.41	5-Chloro- <i>N</i> -(2-(4-(2-fluorophenyl)-1-piperazinyl carbonyl)-4-methoxyphenyl)-thiophene-2-carboxamide (200)	181
5.1.42	5-Chloro- <i>N</i> -(2-(4-(4-fluorophenyl)-1-piperazinyl carbonyl)-4-methoxyphenyl)-thiophene-2-carboxamide (201)	182
5.1.43	5-Chloro- <i>N</i> -(2-(4-(4-chlorophenyl)-1-piperazinyl carbonyl)-4-methoxyphenyl)-thiophene-2-carboxamide (202)	183
5.1.44	5-Chloro- <i>N</i> -(2-(4-(4-methylphenyl)-1-piperazinyl carbonyl)-4,5-dimethoxyphenyl)-thiophene-2-carboxamide (203)	183
5.1.45	5-Chloro- <i>N</i> -(2-(4-(2-methylphenyl)-1-piperazinyl carbonyl)-4,5-dimethoxyphenyl)-thiophene-2-carboxamide (204)	184
5.1.46	5-Chloro- <i>N</i> -(2-(4-(4-methoxyphenyl)-1-piperazinyl carbonyl)-4,5-dimethoxyphenyl)-thiophene-2-carboxamide (205)	184
5.1.47	5-Chloro- <i>N</i> -(2-(4-(2-methoxyphenyl)-1-piperazinyl carbonyl)-4,5-dimethoxyphenyl)-thiophene-2-carboxamide (206)	185
5.1.48	5-Chloro- <i>N</i> -(2-(4-(2-fluorophenyl)-1-piperazinyl carbonyl)-4,5-dimethoxyphenyl)-thiophene-2-carboxamide (207)	185
5.1.49	5-Chloro- <i>N</i> -(2-(4-(4-fluorophenyl)-1-piperazinyl carbonyl)-4,5-dimethoxyphenyl)-thiophene-2-carboxamide (208)	186
5.1.50	5-Chloro- <i>N</i> -(2-(4-(2-chlorophenyl)-1-piperazinyl carbonyl)-4,5-dimethoxyphenyl)-thiophene-2-carboxamide (209)	186
5.1.51	5-Chloro- <i>N</i> -(2-(4-(4-chlorophenyl)-1-piperazinyl carbonyl)-4,5-dimethoxyphenyl)-thiophene-2-carboxamide (210)	187
5.1.52	5-Chloro- <i>N</i> -(2-(4-(4-cyanophenyl)-1-piperazinyl carbonyl)-4,5-dimethoxyphenyl)-thiophene-2-carboxamide (211)	187

5.1.53	5-Chloro- <i>N</i> -(2-(4-(2-cyanophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-thiophene-2-carboxamide (212)	188
5.1.54	5-Chloro- <i>N</i> -(2-(4-(4-nitrophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-thiophene-2-carboxamide (213)	189
5.1.55	5-Chloro- <i>N</i> -(2-(4-(4-aminophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-thiophene-2-carboxamide (214)	189
5.1.56	5-Chloro- <i>N</i> -(2-(4-(4-methylphenyl)-1-piperazinylcarbonyl)-4-chlorophenyl)-thiophene-2-carboxamide (215)	189
5.1.57	5-Chloro- <i>N</i> -(2-(4-(4-methoxyphenyl)-1-piperazinylcarbonyl)-4-chlorophenyl)-thiophene-2-carboxamide (216)	190
5.1.58	5-Chloro- <i>N</i> -(2-(4-(2-methoxyphenyl)-1-piperazinylcarbonyl)-4-chlorophenyl)-thiophene-2-carboxamide (217)	191
5.1.59	5-Chloro- <i>N</i> -(2-(4-(2-fluorophenyl)-1-piperazinylcarbonyl)-4-chlorophenyl)-thiophene-2-carboxamide (218)	191
5.1.60	5-Chloro- <i>N</i> -(2-(4-(4-fluorophenyl)-1-piperazinylcarbonyl)-4-chlorophenyl)-thiophene-2-carboxamide (219)	192
5.1.61	5-Chloro- <i>N</i> -(2-(4-(2-cyanophenyl)-1-piperazinylcarbonyl)-4-chlorophenyl)-thiophene-2-carboxamide (220)	192
5.1.62	5-Chloro- <i>N</i> -(2-(4-(4-cyanophenyl)-1-piperazinylcarbonyl)-4-chlorophenyl)-thiophene-2-carboxamide (221)	193
5.1.63	5-Chloro- <i>N</i> -(2-(4-(4-nitrophenyl)-1-piperazinylcarbonyl)-4-chlorophenyl)-thiophene-2-carboxamide (222)	193
5.1.64	5-Chloro- <i>N</i> -(2-(4-(4-aminophenyl)-1-piperazinylcarbonyl)-4-chlorophenyl)-thiophene-2-carboxamide (223)	193
5.1.65	6-Chloro- <i>N</i> -(2-(4-(4-methylphenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-nicotinamide (224)	194
5.1.66	6-Chloro- <i>N</i> -(2-(4-(2-methylphenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-nicotinamide (225)	195
5.1.67	6-Chloro- <i>N</i> -(2-(4-(2-methoxyphenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-nicotinamide (226)	195
5.1.68	6-Chloro- <i>N</i> -(2-(4-(2-fluorophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-nicotinamide (227)	196
5.1.69	6-Chloro- <i>N</i> -(2-(4-(4-fluorophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-nicotinamide (228)	196

5.1.70	6-Chloro- <i>N</i> -(2-(4-(4-chlorophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl) nicotinamide (229)	197
5.1.71	6-Chloro- <i>N</i> -(2-(4-(4-nitrophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-nicotinamide (230)	197
5.1.72	6-Chloro- <i>N</i> -(2-(4-(4-aminophenyl)-1-piperazinylcarbonyl)-4,5-dimethoxyphenyl)-nicotinamide (231)	198
5.1.73	6-Chloro- <i>N</i> -(4-chloro-2-(4-(4-methylphenyl)-1-piperazinyl carbonyl)-phenyl)-nicotinamide (232)	198
5.1.74	6-Chloro- <i>N</i> -(4-chloro-2-(4-(2-methoxyphenyl)-1-piperazinyl carbonyl)-phenyl)-nicotinamide (233)	199
5.1.75	6-Chloro- <i>N</i> -(4-chloro-2-(4-(4-fluorophenyl)-1-piperazinyl carbonyl)-phenyl)-nicotinamide (234)	199
5.1.76	6-Chloro- <i>N</i> -(4-chloro-2-(4-(2-fluorophenyl)-1-piperazinyl carbonyl)-phenyl)-nicotinamide (235)	200
5.1.77	Diethyl 2-amino-5-methylfuran-3,4-dicarboxylate (238)	200
5.1.78	Ethyl-2-(chloromethyl)-3,4-dihydro-6-methyl-4-oxofuro [2,3- <i>d</i>]pyrimidine-5-carboxylate (239)	201
5.1.79	Ethyl-2-(chloromethyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro [2,3- <i>d</i>]pyrimidine-5-carboxylate (240)	201
5.1.80	Ethyl-2-((4-chlorophenylamino)methyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3 <i>d</i>]-pyrimidine-5-carboxylate (242)	202
5.1.81	Ethyl-2-((4-fluorophenylamino)methyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3 <i>d</i>]-pyrimidine-5-carboxylate (243)	203
5.1.82	Ethyl-2-((3-chloro-4-fluorophenylamino)methyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxylate (244)	203
5.1.83	Ethyl-2-((4-cyanophenylamino)methyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3 <i>d</i>]-pyrimidine-5-carboxylate (245)	204
5.1.84	Ethyl-2-((4-ethylphenylamino)methyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3 <i>d</i>]-pyrimidine-5-carboxylate (246)	204
5.1.85	Ethyl-2-((4-methoxyphenylamino)methyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxylate (247)	205
5.1.86	Ethyl-2-((5-chloropyridin-2-ylamino)methyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro-[2,3 <i>d</i>]pyrimidine-5-carboxylate (248)	205
5.1.87	Ethyl-2-((4-chlorophenoxy)methyl)-3,4-dihydro-3,6-dimethyl	206

	-4-oxofuro[2,3d]-pyrimidine-5-carboxylate (249)	
5.1.88	Ethyl-2-((4-fluorophenoxy)methyl)-3,4-dihydro-3,6-dimethyl -4-oxofuro[2,3d]-pyrimidine-5-carboxylate (250)	206
5.1.89	Ethyl-2-((4-cyanophenoxy)methyl)-3,4-dihydro-3,6-dimethyl -4-oxofuro[2,3d]-pyrimidine-5-carboxylate (251)	207
5.1.90	2-((4-Chlorophenylamino)methyl)-3,4-dihydro-3,6-dimethyl-4- oxo- <i>N</i> -phenethylfuro-[2,3- <i>d</i>]pyrimidine-5-carboxamide (253)	207
5.1.91	2-((4-Chlorophenylamino)methyl)-3,4-dihydro-3,6-dimethyl-4- oxo- <i>N</i> -(2-(pyridin-2-yl)ethyl)furo[2,3- <i>d</i>]pyrimidine-5-carboxamide (254)	208
5.1.92	2-((4-Chlorophenylamino)methyl)- <i>N</i> -(4-fluorophenethyl)-3,4- dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (255)	209
5.1.93	2-((4-Chlorophenylamino)methyl)- <i>N</i> -(4-methoxyphenethyl)-3,4- dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (256)	209
5.1.94	2-((4-Chlorophenylamino)methyl)- <i>N</i> -(4-methylphenethyl)-3,4- dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (257)	210
5.1.95	2-((4-Fluorophenylamino)methyl)-3,4-dihydro-3,6-dimethyl-4-oxo - <i>N</i> -phenethylfuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (258)	210
5.1.96	2-((4-Fluorophenylamino)methyl)- <i>N</i> -(4-chlorophenethyl)-3,4- dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (259)	211
5.1.97	2-((4-Fluorophenylamino)methyl)- <i>N</i> -(4-methoxyphenethyl)-3,4- dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (260)	212
5.1.98	2-((4-Fluorophenylamino)methyl)- <i>N</i> -(4-methylphenethyl)-3,4-dihydro -3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (261)	212
5.1.99	2-((3-Chloro-4-fluorophenylamino)methyl)-3,4-dihydro-3,6- dimethyl-4-oxo- <i>N</i> -phenethylfuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (262)	213
5.1.100	2-((3-Chloro-4-fluorophenylamino)methyl)- <i>N</i> -(4-chlorophenethyl)-3,4- dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (263)	213
5.1.101	2-((3-Chloro-4-fluorophenylamino)methyl)- <i>N</i> -(4-fluorophenethyl) -3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (264)	214
5.1.102	2-((3-Chloro-4-fluorophenylamino)methyl)- <i>N</i> -(4-methoxyphenethyl) -3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (265)	214
5.1.103	2-((3-Chloro-4-fluorophenylamino)methyl)- <i>N</i> -(4-methylphenethyl) -3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (266)	215
5.1.104	2-((4-Cyanophenylamino)methyl)-3,4-dihydro-3,6-dimethyl-4-oxo	216

	- <i>N</i> -phenethylfuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (267)	
5.1.105	2-((4-Cyanophenylamino)methyl)- <i>N</i> -(4-methylphenethyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (268)	216
5.1.106	2-((4-Cyanophenylamino)methyl)- <i>N</i> -(4-fluorophenethyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (269)	217
5.1.107	2-((4-Cyanophenylamino)methyl)- <i>N</i> -(4-chlorophenethyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (270)	218
5.1.108	2-((4-Cyanophenylamino)methyl)- <i>N</i> -(4-methoxyphenethyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (271)	218
5.1.109	2-((4-Cyanophenoxy)methyl)-3,4-dihydro-3,6-dimethyl-4-oxo- <i>N</i> -phenethyl-furo[2,3- <i>d</i>]pyrimidine-5-carboxamide (272)	219
5.1.110	2-((4-Cyanophenoxy)methyl)- <i>N</i> -(4-fluorophenethyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (273)	220
5.1.111	2-((4-Cyanophenoxy)methyl)- <i>N</i> -(4-chlorophenethyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (274)	220
5.1.112	2-((4-Cyanophenoxy)methyl)-3,4-dihydro-3,6-dimethyl-4-oxo- <i>N</i> -(2-(pyridin-2-yl)ethyl)furo[2,3- <i>d</i>]pyrimidine-5-carboxamide (275)	221
5.1.113	2-((4-Cyanophenoxy)methyl)- <i>N</i> -(4-methylphenethyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (276)	221
5.1.114	2-((4-Chlorophenoxy)methyl)-3,4-dihydro-3,6-dimethyl-4-oxo- <i>N</i> -phenethyl-furo[2,3- <i>d</i>]pyrimidine-5-carboxamide (277)	222
5.1.115	2-((4-Chlorophenoxy)methyl)- <i>N</i> -(4-fluorophenethyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (278)	223
5.1.116	2-((4-Fluorophenoxy)methyl)-3,4-dihydro-3,6-dimethyl-4-oxo- <i>N</i> -phenethyl-furo[2,3- <i>d</i>]pyrimidine-5-carboxamide (279)	223
5.1.117	2-((4-Fluorophenoxy)methyl)- <i>N</i> -(4-chlorophenethyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (280)	224
5.1.118	2-((4-Methoxyphenylamino)methyl)- <i>N</i> -(4-fluorophenethyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (281)	224
5.1.119	2-((5-Chloropyridin-2-ylamino)methyl)- <i>N</i> -(4-methylphenethyl)-3,4-dihydro-3,6-dimethyl-4-oxofuro[2,3- <i>d</i>]pyrimidine-5-carboxamide (282)	225
5.2	Biological evaluation	225
5.2.1	<i>In vitro</i> FXa and thrombin inhibition activity	226
5.2.2	Evaluation of test compounds for <i>ex vivo</i> prothrombin time	227

	(PT) and activated partial thromboplastin time (aPTT) prolongation in rats	
5.2.3	<i>In vivo</i> rat tail-bleeding model	227
5.3	Molecular Docking and Simulation studies	227
5.3.1	Molecular dynamics studies	228
5.3.2	Unbiased MD simulation	228
5.4	References	229
6	CONCLUSION	232
7	SUPPLEMENTARY	

LIST OF FIGURES

Figure 1.1	Thrombosis	2
Figure 1.2	Deep vein thrombosis	3
Figure 1.3	Classical Coagulation cascade and the targets for antithrombotic agents	4
Figure 1.4	Cell based-model of coagulation cascade	6
Figure 1.5	Classification of antithrombotic agents	7
Figure 1.6	Factor Xa enzyme with binding sites, subsites and residues	14
Figure 1.7	Schechter and Berger nomenclature for numbering on serine protease enzyme and peptide substrate	15
Figure 1.8	Graphical representation of general structure of FXa inhibitors	17
Figure 1.9	Commonly used central scaffolds or linkers in FXa inhibitors	18
Figure 1.10	Commonly used P1 moieties in FXa inhibitors	18
Figure 1.11	Commonly used P4 motifs in FXa inhibitors	19
Figure 1.12	Human thrombin enzyme active sites (left) and 3-D thrombin structure (right)	22
Figure 1.13	Development of early small molecular weight direct thrombin inhibitors	24
Figure 1.14	Mechanism of thrombin binding with different antithrombotic agents	27
Figure 1.15	Worldwide sales of antithrombotic drugs in 2017	31
Figure 3.1	Designing of FXa inhibitory anthranilamide target compounds.	76
Figure 3.2	Designing of thrombin inhibitory furanopyrimidinone compounds	77
Figure 4.1	<i>In vitro</i> FXa inhibition activity of 4-chlorophenyl derivatives (177-197)	115
Figure 4.2	<i>In vitro</i> FXa inhibition activity of 5-chlorothiophenyl derivatives (198-223)	116
Figure 4.3	<i>In vitro</i> FXa inhibition activity of 6-chloropyridyl derivatives (224-235)	116
Figure 4.4	Molecular docking and molecular dynamics simulation studies	124
Figure 4.5	2D interaction map for compound (201) with FXa after molecular dynamics simulation.	125
Figure 4.6	<i>In vitro</i> FIIa inhibition activity of furanopyrimidinone derivatives (253-267)	153
Figure 4.7	<i>In vitro</i> FIIa inhibition activity of furanopyrimidinone derivatives (268-282)	154
Figure 4.8	2D interaction pose for compound (255) with thrombin enzyme	158

Figure 4.9 Overlaid structure of compound (**255**) and dabigatran with thrombin enzyme

LIST OF TABLES

Table 1.1	Currently approved oral FXa inhibitors with their pharmacological properties	20
Table 1.2	Pharmacological and clinical properties of direct thrombin inhibitors	26
Table 1.3	Current antithrombotic drugs with their side effects	29
Table 1.4	Current oral anticoagulants under development	32
Table 4.1	Infra-red data of intermediate compounds (159-167)	82
Table 4.2	Infra-red data of intermediate compounds (168-175)	83
Table 4.3	IC ₅₀ values of selected compounds for FXa inhibitory activity	117
Table 4.4	<i>Ex vivo</i> PT and aPTT prolongation in rats	118
Table 4.5	<i>In vivo</i> bleeding time in rats	119
Table 4.6	Docking score (ChemGauss4) and computed MM/GBSA binding free energy for the predicted pose of ligand bound to FXa receptor proteins.	125
Table 4.7	Calculated physicochemical and pharmacokinetic properties of the synthesized compounds and rivaroxaban	127
Table 4.8	IC ₅₀ values of compounds for FIIa inhibitory activity	154
Table 4.9	<i>Ex vivo</i> PT and aPTT prolongation in rats	156
Table 4.10	Molecular Docking scores of some selected target compounds	157
Table 4.11	Calculated physicochemical and pharmacokinetic properties of the synthesized compounds and Dabigatran	159